IN2012DN02645A - - Google Patents

Download PDF

Info

Publication number: IN2012DN02645A
Authority: IN; India
Prior art keywords: adamts13; formulations; various diseases; present; conditions
Prior art date: 2009-09-21

Application number

Other languages

English (en)

Inventor

Peter Matthiessen H

L Turecek Peter

Schwarz Hans-Peter

Original Assignee

Baxter Int

Baxter Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-21

Filing date

2010-09-21

Publication date

2015-09-11

2010-09-21 Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int

2015-09-11 Publication of IN2012DN02645A publication Critical patent/IN2012DN02645A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Inorganic Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Dispersion Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IN2645DEN2012 2009-09-21 2010-09-21 IN2012DN02645A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24435309P	2009-09-21	2009-09-21
PCT/US2010/049723 WO2011035335A2 (fr)	2009-09-21	2010-09-21	Compositions d'adamts13 liquides stabilisées et lyophilisées

Publications (1)

Publication Number	Publication Date
IN2012DN02645A true IN2012DN02645A (fr)	2015-09-11

Family

ID=43598388

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2645DEN2012 IN2012DN02645A (fr)	2009-09-21	2010-09-21

Country Status (21)

Country	Link
US (9)	US8623352B2 (fr)
EP (5)	EP3167897B1 (fr)
JP (2)	JP5819303B2 (fr)
KR (6)	KR20190137954A (fr)
CN (2)	CN104224705B (fr)
AU (1)	AU2010295299B2 (fr)
BR (1)	BR112012006283B1 (fr)
CA (1)	CA2774556A1 (fr)
DK (4)	DK3834841T3 (fr)
EA (1)	EA024267B1 (fr)
ES (4)	ES2865250T3 (fr)
FI (2)	FI3834841T3 (fr)
FR (1)	FR24C1049I1 (fr)
HR (1)	HRP20160295T1 (fr)
HU (1)	HUE028688T2 (fr)
IN (1)	IN2012DN02645A (fr)
MX (3)	MX362382B (fr)
NZ (1)	NZ598839A (fr)
PL (4)	PL2480198T3 (fr)
PT (2)	PT4218797T (fr)
WO (1)	WO2011035335A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8415114B2 (en) *	2008-12-05	2013-04-09	Baxter International Inc.	Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
JP5819303B2 (ja) *	2009-09-21	2015-11-24	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤
JP6170077B2 (ja) *	2012-02-16	2017-07-26	エータイアーファーマ，インコーポレイテッド	自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素
CN103566362B (zh) *	2012-07-21	2015-07-29	复旦大学	重组adamts13在制备脑出血药物中的用途
CA2890848C (fr)	2012-11-09	2020-11-17	Puget Sound Blood Center	Facteurs de stabilisation de proteine apolipoproteine a-1 ou de lipoproteine haute densite
ES2708565T3 (es)	2013-03-15	2019-04-10	Atyr Pharma Inc	Conjugados de Fc-histidil-ARNt sintetasa
AU2013203062C1 (en) *	2013-03-15	2018-06-28	Takeda Pharmaceutical Company Limited	Subcutaneous administration of adamts13
EP4285930A3 (fr) *	2014-06-26	2024-02-28	Amgen Inc.	Formulations de protéines
GB201510870D0 (en) *	2015-05-26	2015-08-05	Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh	Treatment of infarction
JP7002727B2 (ja) *	2016-01-08	2022-02-15	Ｋｍバイオロジクス株式会社	Ａｄａｍｔｓ１３を主成分とする診断薬および医薬品
NZ750146A (en) *	2016-08-04	2025-10-31	Takeda Pharmaceuticals Co	Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
JP7545210B2 (ja)	2016-11-04	2024-09-04	武田薬品工業株式会社	アデノ随伴ウイルス製剤
EP3612215B1 (fr)	2017-04-20	2024-08-28	aTyr Pharma, Inc.	Compositions pour le traitement d'inflammation pulmonaire
TWI810196B (zh) *	2017-07-25	2023-08-01	大陸商江蘇恆瑞醫藥股份有限公司	一種il-15蛋白質複合物醫藥組成物及其用途
MX2020013953A (es) *	2018-07-11	2021-03-09	Takeda Pharmaceuticals Co	Composiciones de virus adenoasociado (aav).
WO2021067668A1 (fr)	2019-10-04	2021-04-08	The Children's Medical Center Corporation	Traitement à base d'adamts13 pour améliorer la survie de greffon
AU2021248679A1 (en)	2020-04-02	2022-10-27	Takeda Pharmaceutical Company Limited	ADAMTS13 variant, compositions, and uses thereof
WO2021234458A1 (fr)	2020-05-22	2021-11-25	Takeda Pharmaceutical Company Limited	Compositions d'adamts13 et méthodes de traitement et de diagnostic de complications d'une maladie à coronavirus
IL300596A (en) *	2020-08-13	2023-04-01	Hadasit Medical Res Services & Development Limited	Mutants of disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (adamts-13), preparations and their uses in therapeutic methods
EP4490042A1 (fr)	2022-03-08	2025-01-15	Equashield Medical Ltd.	Station de transfert de fluide dans un système de préparation pharmaceutique robotique
WO2024151093A1 (fr) *	2023-01-11	2024-07-18	주식회사 녹십자	Nouvelle formulation liquide pour la prévention ou le traitement d'une maladie thrombotique

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5250421A (en)	1986-01-03	1993-10-05	Genetics Institute, Inc.	Method for producing factor VIII:C-type proteins
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en)	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en)	1997-06-20	2002-11-05	Baxter Aktiengesellschaft	Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de)	1997-06-20	2001-02-26	Immuno Ag	Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
ES2435141T3 (es)	1999-02-22	2013-12-18	University Of Connecticut	Nuevas formulaciones de factor VIII libres de albúmina
JP2001227510A (ja)	2000-02-15	2001-08-24	Tomoe Tech Res Co	複作動型の空気式アクチュエータ
JP3783507B2 (ja)	2000-02-16	2006-06-07	日本精工株式会社	トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) *	2000-11-22	2005-08-09	Baxter Aktiengesellschaft	Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja)	2001-04-25	2003-10-07	Chemo Sero Therapeut Res Inst	フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) *	2001-08-16	2006-05-02	Regents Of University Of Michigan	Methods and compositions for detecting variant ADAMTS13 genes
ITPR20010055A1 (it)	2001-08-31	2003-03-03	Vetroarredo Spa	Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko)	2002-10-09	2005-03-10	동부아남반도체 주식회사	모스 트랜지스터 제조 방법
WO2005008241A1 (fr) *	2003-07-07	2005-01-27	University Of North Carolina At Chapel Hill	Procede et systeme de detection de multimeres du facteur von willebrand (vwf)
GB0404693D0 (en) *	2004-03-02	2004-04-07	Univ London	Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en)	2004-10-29	2006-05-04	Leopold Grillberger	Animal protein-free media for cultivation of cells
AU2006257073B2 (en)	2005-06-17	2011-08-04	Children's Medical Center Corporation	ADAMTS13-comprising compositions having thrombolytic activity
JP4880997B2 (ja) *	2005-12-28	2012-02-22	アルフレッサファーマ株式会社	Ａｄａｍｔｓ１３の安定化方法
ES2474573T3 (es)	2006-01-04	2014-07-09	Baxter International Inc	Medio de cultivo celular sin oligop�ptidos
JP5819303B2 (ja) *	2009-09-21	2015-11-24	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤
US8823352B2 (en)	2011-07-11	2014-09-02	Linear Technology Corporation	Switching power supply having separate AC and DC current sensing paths

2010
- 2010-09-21 JP JP2012529982A patent/JP5819303B2/ja active Active
- 2010-09-21 FI FIEP20211228.0T patent/FI3834841T3/fi active
- 2010-09-21 HR HRP20160295TT patent/HRP20160295T1/hr unknown
- 2010-09-21 KR KR1020197035791A patent/KR20190137954A/ko not_active Ceased
- 2010-09-21 PT PT231727595T patent/PT4218797T/pt unknown
- 2010-09-21 CN CN201410452647.8A patent/CN104224705B/zh active Active
- 2010-09-21 KR KR1020127009803A patent/KR101891646B1/ko active Active
- 2010-09-21 IN IN2645DEN2012 patent/IN2012DN02645A/en unknown
- 2010-09-21 EP EP15203085.4A patent/EP3167897B1/fr active Active
- 2010-09-21 CA CA2774556A patent/CA2774556A1/fr not_active Abandoned
- 2010-09-21 US US12/887,424 patent/US8623352B2/en active Active
- 2010-09-21 BR BR112012006283-2A patent/BR112012006283B1/pt active IP Right Grant
- 2010-09-21 PL PL10759786.6T patent/PL2480198T3/pl unknown
- 2010-09-21 ES ES15203085T patent/ES2865250T3/es active Active
- 2010-09-21 DK DK20211228.0T patent/DK3834841T3/da active
- 2010-09-21 PT PT202112280T patent/PT3834841T/pt unknown
- 2010-09-21 WO PCT/US2010/049723 patent/WO2011035335A2/fr not_active Ceased
- 2010-09-21 PL PL23172759.5T patent/PL4218797T3/pl unknown
- 2010-09-21 ES ES23172759T patent/ES3001509T3/es active Active
- 2010-09-21 DK DK23172759.5T patent/DK4218797T5/da active
- 2010-09-21 KR KR1020187023806A patent/KR20180095738A/ko not_active Ceased
- 2010-09-21 DK DK10759786.6T patent/DK2480198T3/en active
- 2010-09-21 KR KR1020217013486A patent/KR20210054598A/ko not_active Ceased
- 2010-09-21 ES ES20211228T patent/ES2948612T3/es active Active
- 2010-09-21 KR KR1020247043292A patent/KR20250008986A/ko active Pending
- 2010-09-21 PL PL15203085T patent/PL3167897T3/pl unknown
- 2010-09-21 ES ES10759786.6T patent/ES2579906T3/es active Active
- 2010-09-21 EP EP10759786.6A patent/EP2480198B9/fr active Active
- 2010-09-21 EA EA201200519A patent/EA024267B1/ru not_active IP Right Cessation
- 2010-09-21 MX MX2016005314A patent/MX362382B/es unknown
- 2010-09-21 DK DK15203085.4T patent/DK3167897T3/da active
- 2010-09-21 KR KR1020227034508A patent/KR20220139456A/ko not_active Ceased
- 2010-09-21 EP EP24192531.2A patent/EP4467160A3/fr active Pending
- 2010-09-21 NZ NZ598839A patent/NZ598839A/en unknown
- 2010-09-21 HU HUE10759786A patent/HUE028688T2/en unknown
- 2010-09-21 EP EP20211228.0A patent/EP3834841B1/fr active Active
- 2010-09-21 CN CN201080046707.6A patent/CN102573792B/zh active Active
- 2010-09-21 AU AU2010295299A patent/AU2010295299B2/en active Active
- 2010-09-21 EP EP23172759.5A patent/EP4218797B9/fr active Active
- 2010-09-21 MX MX2012003414A patent/MX339205B/es active IP Right Grant
- 2010-09-21 PL PL20211228.0T patent/PL3834841T3/pl unknown
- 2010-09-21 FI FIEP23172759.5T patent/FI4218797T3/fi active
2012
- 2012-03-21 MX MX2019000547A patent/MX2019000547A/es unknown
2013
- 2013-11-22 US US14/088,169 patent/US9351935B2/en active Active
2014
- 2014-12-24 JP JP2014259954A patent/JP2015063556A/ja active Pending
2016
- 2016-05-03 US US15/145,755 patent/US9572778B2/en active Active
2017
- 2017-01-06 US US15/400,526 patent/US9937244B2/en active Active
2018
- 2018-02-28 US US15/908,213 patent/US10238720B2/en active Active
2019
- 2019-02-14 US US16/275,690 patent/US10758599B2/en active Active
2020
- 2020-07-21 US US16/934,100 patent/US11564979B2/en active Active
2022
- 2022-12-23 US US18/146,212 patent/US12178861B2/en active Active
2024
- 2024-11-19 US US18/952,409 patent/US20250099559A1/en active Pending
- 2024-12-10 FR FR24C1049C patent/FR24C1049I1/fr active Active

Also Published As

Publication number	Publication date
CN104224705B (zh)	2018-02-02
AU2010295299B2 (en)	2015-12-24
NZ598839A (en)	2014-03-28
MX2019000547A (es)	2020-11-12
DK4218797T3 (da)	2024-12-09
CA2774556A1 (fr)	2011-03-24
KR20120099646A (ko)	2012-09-11
DK3834841T3 (da)	2023-06-06
FR24C1049I1 (fr)	2025-01-17
US20180207245A1 (en)	2018-07-26
US20230130866A1 (en)	2023-04-27
MX2012003414A (es)	2012-06-19
US9572778B2 (en)	2017-02-21
KR20210054598A (ko)	2021-05-13
HRP20160295T1 (hr)	2016-05-20
HK1173968A1 (zh)	2013-05-31
MX362382B (es)	2019-01-14
DK4218797T5 (da)	2025-07-21
CN104224705A (zh)	2014-12-24
BR112012006283B1 (pt)	2022-03-15
EP4218797B1 (fr)	2024-09-11
PT3834841T (pt)	2023-06-19
KR20190137954A (ko)	2019-12-11
ES3001509T3 (en)	2025-03-05
US11564979B2 (en)	2023-01-31
DK2480198T3 (en)	2016-03-29
US9937244B2 (en)	2018-04-10
BR112012006283A2 (pt)	2016-05-31
KR20220139456A (ko)	2022-10-14
EP2480198B9 (fr)	2016-11-23
PL3167897T3 (pl)	2021-09-27
EA201200519A1 (ru)	2012-09-28
US20250099559A1 (en)	2025-03-27
US20160375111A1 (en)	2016-12-29
JP2015063556A (ja)	2015-04-09
US20110229455A1 (en)	2011-09-22
WO2011035335A3 (fr)	2011-12-01
KR101891646B1 (ko)	2018-08-27
CN102573792A (zh)	2012-07-11
KR20250008986A (ko)	2025-01-16
PL4218797T3 (pl)	2025-02-10
PT4218797T (pt)	2024-12-09
US20170112906A1 (en)	2017-04-27
US9351935B2 (en)	2016-05-31
ES2579906T3 (es)	2016-08-17
US20190247475A1 (en)	2019-08-15
ES2948612T3 (es)	2023-09-14
EP4218797A1 (fr)	2023-08-02
FI4218797T3 (fi)	2024-12-07
EP2480198A2 (fr)	2012-08-01
US10758599B2 (en)	2020-09-01
DK3167897T3 (da)	2021-04-19
EA024267B1 (ru)	2016-09-30
US10238720B2 (en)	2019-03-26
EP3167897A1 (fr)	2017-05-17
JP5819303B2 (ja)	2015-11-24
US12178861B2 (en)	2024-12-31
AU2010295299A1 (en)	2012-04-12
EP3834841B1 (fr)	2023-05-17
US8623352B2 (en)	2014-01-07
EP3834841A1 (fr)	2021-06-16
US20200376098A1 (en)	2020-12-03
US20140178357A1 (en)	2014-06-26
PL3834841T3 (pl)	2023-07-24
ES2865250T3 (es)	2021-10-15
EP3167897B1 (fr)	2021-01-27
MX339205B (es)	2016-05-16
JP2013505270A (ja)	2013-02-14
PL2480198T3 (pl)	2016-09-30
EP2480198B1 (fr)	2016-03-09
CN102573792B (zh)	2014-10-15
EP4467160A3 (fr)	2025-01-15
EP4218797B9 (fr)	2025-03-05
FI3834841T3 (fi)	2023-06-05
WO2011035335A2 (fr)	2011-03-24
KR20180095738A (ko)	2018-08-27
HUE028688T2 (en)	2017-01-30
EP4467160A2 (fr)	2024-11-27

Publication	Publication Date	Title
IN2012DN02645A (fr)	2015-09-11
UA108198C2 (uk)	2015-04-10	Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2013006040A (es)	2013-08-26	Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
UA115983C2 (uk)	2018-01-25	Інгібітори днк-пк
TN2012000126A1 (en)	2013-09-19	Polycyclic compounds as lysophosphatidic acid receptor antagonists
HK1203356A1 (en)	2015-10-30	Pharmaceutical combinations comprising a thionucleotide analog
WO2012024620A3 (fr)	2012-05-18	Inhibiteurs de l'autotaxine et leurs utilisations
IN2012DN02737A (fr)	2015-09-11
WO2012088266A3 (fr)	2012-08-16	Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
IN2012DN02177A (fr)	2015-08-21
IN2012DN00754A (fr)	2015-06-19
AU2012253757A8 (en)	2015-10-22	Partially saturated tricyclic compounds and methods of making and using same
MD20150035A2 (ro)	2015-10-31	Inhibitori de tirozinkinaza Bruton
TN2010000122A1 (en)	2011-09-26	Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl)	2011-03-31	Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MX2013004061A (es)	2013-07-22	Analogos de ciclosporina.
MX2012004078A (es)	2012-07-25	Compuestos y composiciones como moduladores de la actividad de gpr119.
DE602007010764D1 (en)	2011-01-05	Benzamidglucokinaseaktivatoren
MX2011013032A (es)	2012-02-08	Inhibidores de fosfatidilinositol 3-cinasa.
MY164998A (en)	2018-02-28	Isoquinolinone derivatives as nk3 antagonists
MX2013004062A (es)	2013-07-22	Analogos de ciclosporina.
MX2011008645A (es)	2011-09-30	Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
WO2014100857A8 (fr)	2014-11-06	Vaccins pour traiter le cancer et compositions pour améliorer l'efficacité des vaccins
EP2597949A4 (fr)	2014-01-15	Compositions submicroniques
WO2011091154A3 (fr)	2012-01-05	Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer